tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ALT Stock Latest News

Altimmune announces publication of IMPACT Phase 2b trial data
The FlyAltimmune announces publication of IMPACT Phase 2b trial data
18d ago
ALT
Altimmune announce results from analysis of biopsies from IMPACT Phase 2b trial
PremiumThe Fly
Altimmune announce results from analysis of biopsies from IMPACT Phase 2b trial
22d ago
ALT
Altimmune price target lowered to $14 from $15 at Citizens JMP
PremiumThe Fly
Altimmune price target lowered to $14 from $15 at Citizens JMP
22d ago
ALT
Altimmune Reports Q3 2025 Financial and Business Progress
PremiumCompany Announcements
Altimmune Reports Q3 2025 Financial and Business Progress
22d ago
ALT
Altimmune’s Earnings Call: Financial Growth and Clinical Progress
PremiumCompany Announcements
Altimmune’s Earnings Call: Financial Growth and Clinical Progress
22d ago
ALT
Altimmune’s Clinical Progress and Financial Maneuvers Justify Hold Rating Amid Transitional Phase
PremiumRatingsAltimmune’s Clinical Progress and Financial Maneuvers Justify Hold Rating Amid Transitional Phase
22d ago
ALT
Altimmune Enters New Equity Distribution Agreement
Premium
Company Announcements
Altimmune Enters New Equity Distribution Agreement
23d ago
8K
ALT
Altimmune files $400M mixed securities shelf
Premium
The Fly
Altimmune files $400M mixed securities shelf
23d ago
ALT
Altimmune Amends Loan Agreement with Hercules Capital
PremiumCompany Announcements
Altimmune Amends Loan Agreement with Hercules Capital
23d ago
8K
ALT
Altimmune reports Q3 EPS (21c), consensus (27c)
PremiumThe Fly
Altimmune reports Q3 EPS (21c), consensus (27c)
23d ago
ALT
ALT Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
ALT Upcoming Earnings Report: What to Expect?
25d ago
ALT
Altimmune announces early completion of enrollment in RECLAIM Phase 2 trial
PremiumThe Fly
Altimmune announces early completion of enrollment in RECLAIM Phase 2 trial
26d ago
ALT
Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment
PremiumCompany AnnouncementsAltimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment
1M ago
ALT
Altimmune’s RECLAIM STUDY: A New Hope for Alcohol Use Disorder Treatment
Premium
Company Announcements
Altimmune’s RECLAIM STUDY: A New Hope for Alcohol Use Disorder Treatment
1M ago
ALT
Altimmune’s Strategic Leadership and Promising Clinical Data Drive Buy Rating
Premium
Ratings
Altimmune’s Strategic Leadership and Promising Clinical Data Drive Buy Rating
1M ago
ALT
Altimmune Appoints New Chief Medical Officer
PremiumCompany Announcements
Altimmune Appoints New Chief Medical Officer
2M ago
8K
ALT
Altimmune appoints Christophe Arbet-Engels as CMO
PremiumThe Fly
Altimmune appoints Christophe Arbet-Engels as CMO
2M ago
ALT
XFOR
Altimmune Holds Annual Stockholders Meeting on Governance
PremiumCompany Announcements
Altimmune Holds Annual Stockholders Meeting on Governance
2M ago
8K
ALT
ALT Lawsuit Alert! Class Action Lawsuit Against Altimmune
PremiumMarket News
ALT Lawsuit Alert! Class Action Lawsuit Against Altimmune
2M ago
ALT
Altimmune’s Pemvidutide Advances: Analyst Recommends Buy with Promising Trial Milestones and Dual Mechanism Benefits
PremiumRatingsAltimmune’s Pemvidutide Advances: Analyst Recommends Buy with Promising Trial Milestones and Dual Mechanism Benefits
2M ago
ALT
Altimmune appoints Richardson as Chief Commercial Officer
Premium
The Fly
Altimmune appoints Richardson as Chief Commercial Officer
2M ago
ALT
Altimmune’s Earnings Call Highlights NASH Trial Success and Financial Strength
Premium
Company Announcements
Altimmune’s Earnings Call Highlights NASH Trial Success and Financial Strength
3M ago
ALT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >